Advertisement

Supply Chain



Bristol-Myers Squibb will pay Nektar Therapeutics $1 billion to develop a cancer immunotherapy treatment — one of the largest deals ever inked for a single drug's development, reports Reuters.

FDA Commissioner Scott Gottlieb, MD, on Tuesday outlined several initiatives the agency would take to improve patient treatments and lower healthcare costs, using resources proposed in its recent budget request.

Advertisement

Most Read

Advertisement
Advertisement